PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

celecoxib Side Effects

The reactions most often reported to the FDA for celecoxib (also sold as Celebrex), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

128,099
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2003 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of celecoxib come from 128,099 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 128,099 reports to the FDA Adverse Event Reporting System (FAERS) for celecoxib (Celebrex): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

128,099

Reports Mentioning Death

11,737

9.2% of reports — not proof the medicine caused the death

Hospitalizations

39,327

30.7% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

PAIN
12,294
ARTHRALGIA
10,923
FATIGUE
9,710
NAUSEA
9,389
DRUG HYPERSENSITIVITY
7,713
DIARRHOEA
7,296
HEADACHE
7,227
RHEUMATOID ARTHRITIS
7,200
MYOCARDIAL INFARCTION
7,038
MALAISE
6,220
RASH
6,216
PAIN IN EXTREMITY
6,207
DIZZINESS
6,186
CONDITION AGGRAVATED
6,183
DYSPNOEA
6,068
VOMITING
5,816
JOINT SWELLING
5,503
HYPERTENSION
5,249

Who Reports Side Effects

Gender Distribution

Female 83,065 (70%)
Male 35,001 (30%)
Unknown 543

Age Distribution

0-17 1,362 (2%)
18-44 12,254 (16%)
45-64 33,257 (43%)
65-74 17,862 (23%)
75+ 12,385 (16%)

Reporting Trend by Year

2003 2025

Reactions in Death Reports

Top reactions reported in 11,737 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 2,402
FATIGUE 1,849
HYPERTENSION 1,686
VOMITING 1,678
ARTHRALGIA 1,619
GENERAL PHYSICAL HEALTH DETERIORATION 1,615
HYPOAESTHESIA 1,600
DIARRHOEA 1,534
GLOSSODYNIA 1,530
SYSTEMIC LUPUS ERYTHEMATOSUS 1,529
FOLLICULITIS 1,518
TYPE 2 DIABETES MELLITUS 1,515
DYSPNOEA 1,514
RHEUMATOID ARTHRITIS 1,512
HAND DEFORMITY 1,510
DIZZINESS 1,498
PAIN 1,497
ASTHENIA 1,494
DUODENAL ULCER PERFORATION 1,487

Reactions in Hospitalization Reports

Top reactions in 39,327 reports where hospitalization was an outcome.

Reaction Reports
MYOCARDIAL INFARCTION 4,468
PAIN 4,350
ARTHRALGIA 3,914
FATIGUE 3,879
NAUSEA 3,575
DYSPNOEA 3,153
DIARRHOEA 3,143
HYPERTENSION 2,990
VOMITING 2,983
HEADACHE 2,897
RHEUMATOID ARTHRITIS 2,863
CEREBROVASCULAR ACCIDENT 2,831
MALAISE 2,792
PNEUMONIA 2,767
CONDITION AGGRAVATED 2,693
RASH 2,664
JOINT SWELLING 2,627
ASTHENIA 2,581

Compare celecoxib vs abatacept →

What the FAERS Data Reveals About celecoxib Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 128,099 voluntary reports linked to celecoxib and its brand equivalents (Celebrex), spanning 2003 through 2025. Of those, 11,737 (9.2%) listed death as an outcome and 39,327 (30.7%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 70% were female and 30% male; age distribution skews toward 45-64, with 33,257 reports in that bracket. The single most reported reaction is pain with 12,294 submissions, followed by arthralgia and fatigue.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.